LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Lista de Ações・Novartis AG

Novartis AG

Fechado

148.01 -1.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

147.68

Máximo

148.3

Indicadores-chave
By Trading Economics
Rendimento	747M 3.2B
Vendas	189M 14B
P/E Médio do Setor	20.777 51.415
EPS	1.99
Rendimento de Dividendos	3.26
Margem de lucro	23.336
Funcionários	75,267
EBITDA	338M 5.4B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+14.65% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	3.26% 2.34%

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.2B 277B
Abertura anterior	149.19
Fecho anterior	148.01

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

N/A / 112.63 Suporte e Resistência

Novartis AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de abr. de 2026, 09:05 UTC

Ganhos

Novartis Earnings Hit by Generic Competition -- Update

28 de abr. de 2026, 05:51 UTC

Ganhos

Novartis Could Upgrade Future Growth Outlook

27 de mar. de 2026, 10:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 de mar. de 2026, 06:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 de abr. de 2026, 09:18 UTC

Conversa de Mercado

Ganhos

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 de abr. de 2026, 07:26 UTC

Conversa de Mercado

Ganhos

Novartis's Results Are Mixed -- Market Talk

28 de abr. de 2026, 05:07 UTC

Ganhos

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 de abr. de 2026, 05:05 UTC

Ganhos

Novartis: On Track to Deliver Full-Year Guiance

28 de abr. de 2026, 05:04 UTC

Ganhos

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 de abr. de 2026, 05:04 UTC

Ganhos

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 de abr. de 2026, 05:03 UTC

Ganhos

Novartis 1Q Core EPS $1.99

28 de abr. de 2026, 05:03 UTC

Ganhos

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 de abr. de 2026, 05:02 UTC

Ganhos

Novartis 1Q Core Operating Profit $4.90B

28 de abr. de 2026, 05:02 UTC

Ganhos

Analysts Saw Novartis 1Q Sales at $13.34B

28 de abr. de 2026, 05:01 UTC

Ganhos

Novartis 1Q Sales $13.11B

28 de abr. de 2026, 05:00 UTC

Ganhos

Novartis Backs 2026 View

28 de abr. de 2026, 05:00 UTC

Ganhos

Novartis AG 1Q EPS $1.65

28 de abr. de 2026, 05:00 UTC

Ganhos

Novartis AG 1Q Net Pft $3.2B

28 de abr. de 2026, 05:00 UTC

Ganhos

Novartis AG 1Q Adj EPS $1.99

24 de abr. de 2026, 05:20 UTC

Ganhos

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 de abr. de 2026, 05:19 UTC

Ganhos

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 de abr. de 2026, 05:19 UTC

Ganhos

Novartis: Prequalification Is a Process Run by the WHO

10 de abr. de 2026, 11:45 UTC

Conversa de Mercado

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 de abr. de 2026, 08:01 UTC

Conversa de Mercado

Novartis Likely to Confirm Guidance -- Market Talk

30 de mar. de 2026, 09:37 UTC

Conversa de Mercado

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 de mar. de 2026, 07:54 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 de mar. de 2026, 06:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 de mar. de 2026, 06:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 de mar. de 2026, 06:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 de mar. de 2026, 06:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Comparação entre Pares

Variação de preço

Novartis AG Previsão

Preço-alvo

By TipRanks

14.65% parte superior

Previsão para 12 meses

Média 169.78 USD 14.65%

Máximo 180 USD

Mínimo 141 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Novartis AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Novartis AG - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 112.63Suporte e Resistência

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.